Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (NYSE: BDX) is a global leader in medical technology driving advancements in healthcare through innovative devices, diagnostic solutions, and clinical systems. This page provides real-time updates on BD's latest developments, offering investors and professionals a centralized hub for tracking corporate announcements and industry impact.
Access authoritative information including earnings reports, regulatory milestones, product innovations, and strategic partnerships. Our curated news collection helps stakeholders monitor BD's contributions to medication management, diagnostic testing, and surgical care across 190+ countries.
Key updates cover BD Medical safety-engineered products, BD Life Sciences diagnostic platforms, and BD Interventional surgical technologies. Stay informed about developments in smart medication systems, infectious disease testing, and minimally invasive procedures shaping modern healthcare.
Bookmark this page for ongoing insights into BD's operational updates, leadership changes, and R&D breakthroughs. Verify critical information directly through primary sources while maintaining awareness of market trends in the $600B+ medical technology sector.
Waters (NYSE:WAT) and BD have announced a transformative $17.5 billion merger combining BD's Biosciences & Diagnostic Solutions business with Waters through a tax-efficient Reverse Morris Trust transaction. The deal will create a leading life science and diagnostics company with expected 2025 pro forma sales of $6.5 billion and adjusted EBITDA of $2.0 billion.
The merger doubles Waters' total addressable market to $40 billion and increases annual recurring revenue to over 70%. The combined entity expects $345 million in annualized EBITDA synergies by 2030, including $200 million in cost synergies by year three and $290 million in revenue synergies by year five. The transaction is expected to be accretive to adjusted EPS in the first year.
Post-merger, Waters' CEO Udit Batra will lead the combined company, which will maintain the Waters name and NYSE:WAT listing. BD shareholders will own 39.2% of the combined company, while Waters shareholders will retain 60.8%. The deal is expected to close around Q1 2026.
BD (NYSE: BDX) has appointed Bilal Muhsin as Executive Vice President and future President of its Connected Care segment, effective July 2, 2025. Muhsin, who will report to CEO Tom Polen, joins from Masimo where he served as COO during his 25-year tenure.
In this newly created role, Muhsin will lead BD's Connected Care strategy, focusing on advanced analytics and AI solutions alongside smart devices to enhance patient care efficiency. The appointment aligns with BD's transformation into a pure-play MedTech leader, emphasizing connected medication management, advanced workflow robotics, and smart monitoring solutions.
Muhsin brings significant expertise in medical engineering and software development, holding over 50 patents in Medical Systems Communication, Analytics, and Patient Monitoring Systems.
BD (NYSE: BDX) has announced the initiation of XTRACT, a patient data registry to evaluate real-world outcomes of its Rotarex™ Atherectomy System in treating peripheral artery disease (PAD). The registry will enroll up to 600 patients across approximately 100 clinical sites in the United States, with patient follow-ups at 30 days, 6 months, and 12 months post-procedure.
The Rotarex™ System is a minimally invasive device designed to remove both plaque and thrombus in peripheral arteries, serving as both an atherectomy and thrombectomy device. The study, led by Dr. Prakash Krishnan and Dr. Todd Berland, aims to assess the system's clinical performance in treating PAD, a condition affecting over 21 million Americans and 200 million people worldwide.
BD (NYSE: BDX), a leading global medical technology company, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The presentation is scheduled for Monday, June 9, 2025, at 2:00 pm Eastern Time. Investors and interested parties can access the live webcast through BD's investor relations website at investors.bd.com. A replay of the presentation will be made available on the same platform after the event concludes.
BD (NYSE: BDX) has announced it will host an audio webcast on August 7, 2025, at 8 a.m. ET to discuss its third quarter fiscal 2025 financial results. The quarter ends on June 30, 2025. During the webcast, management will present the quarterly financial performance and provide updates on the company's operations and strategy.
The webcast will be accessible through BD's investor relations website, with presentation materials and a summary of financial information to be released prior to the call. A replay of the webcast will be available on the same website shortly after the event.
BD (Becton, Dickinson and Company), a global leader in medical technology, has announced its upcoming participation in the Bank of America Securities Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2025, at 1:00 pm Eastern Time.
Investors and interested parties can access the live webcast through the BD investor relations website at investors.bd.com. For those unable to attend the live presentation, a replay will be made available on the same platform after the event concludes.
BD (Becton, Dickinson and Company), a leading global medical technology company, has announced its latest quarterly dividend declaration. The company's Board of Directors has approved a quarterly dividend of $1.04 per common share.
Key details of the dividend announcement:
- Payment Date: June 30, 2025
- Record Date: June 9, 2025
- Annual Dividend Rate: $4.16 per share
This dividend announcement from the NYSE-listed company (BDX) demonstrates BD's commitment to providing regular returns to its shareholders.